Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Akk4.2
Akkermansia – Forschung
Überwiegend Mechanismus / Beobachtung
32 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Akkermansia sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2019–2026 mit einer typischen Studiengröße von 100 Teilnehmenden.
Basierend auf 32 Studien · 2 Meta-Analysen · 4 RCTs · 4,666 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Digestive health
Überwiegend Mechanismus / Beobachtung10 Studien
Glucose & metabolicMöglicher Nutzen für die Insulinsensitivität (früh/inkonsistent; größere Studie ohne Effekt außer in der Subgruppe mit niedrigem Ausgangswert) · 8-12 weeks · Mögliche Verbesserung der Insulinsensitivität (inkonsistente Evidenz beim Menschen) · 8-12 weeks
31 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
20192026
1Meta-Analysen=2,042 · very large study2026
Further mechanistic, dose-controlled, and long-term human studies are needed to determine whether these microbiota-related changes translate into clinically meaningful outcomes.
Alshatari S, Ziarno M. · Nutrients (2026)
Polyphenol supplementation was associated with an increase in total SCFAs in 70.6% of studies and with significantly higher butyrate concentrations (pooled SMD = 0.48; 95% CI: 0.32-0.64; I 2 = 58%).
Acetate and propionate increased in 75% and 71.4% of studies, respectively.
Increases in alpha diversity were reported in 66.7% of studies, and increases in beta diversity were reported in 87.5%.
Thus, while the relationship between antipsychotic-induced weight gain, metabolic dysfunction, and changes in the gut microbiome are evident, further research is warranted to establish definitive causal relationships and to aid in the development of precision microbiota-targeted interventions to counteract these adverse effects.
Tufvesson-Alm M et al. · Dialogues in clinical neuroscience (2026)
However, there is a lack of consensus with regards to the exact mechanisms and involvement of the microbiome in antipsychotic-induced weight gain.
Nevertheless, a few patterns and common observations were found across studies, such as reduced diversity, increased Firmicutes/Bacteroidetes ratio and a reduction in Akkermansia species.
While microbiota-targeted interventions had generally weak effects on weight gain and metabolic dysfunction in clinical cohorts, the use of specific probiotic strains and microbiota metabolites showed promise in preclinical studies.
With A. muciniphila as an example, we argue that a microbe's specific environment must be considered to enable critical evaluation of next-generation probiotics.
Grant ET, Monzel E, Desai MS. · Nature microbiology (2026)
However, other work indicates that the effects of A. muciniphila vary depending on nutrition, host genetics and the interaction with surrounding microbes.
Furthermore, strain-specific differences in the ability to modulate intestinal barrier function and antimicrobial resistance profiles remain underexplored.
Here, by focusing on potential sources of this variation, we provide a nuanced discussion on the complex role of A. muciniphila in human health.
Beyond live bacteria, advances in pasteurized formulations and bioactive derivatives highlight complementary advantages.
Xie L, Lu J, Han H, Liu Z, Dong C, Wu H, Qiao J. · Frontiers in cellular and infection microbiology (2026)
Akkermansia muciniphila ( A. muciniphila ), a key gut commensal, sustains immune homeostasis and metabolic balance, emerging as a promising next-generation probiotic.
This review synthesizes current evidence on the mechanisms such as regulating the intestinal barrier, immunomodulation, mediating anti-inflammatory metabolites and regulating microbiota and therapeutic potential of A. muciniphila in inflammation-related diseases.
Integrating these with experimental/clinical data across inflammation-related disorders establishes a coherent framework.
Our findings suggest that MedD interventions improve HbA1c, LDL cholesterol, and triglycerides, and promote beneficial GM changes.
Lauria F et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD (2026)
Our findings suggest that MedD interventions improve HbA1c, LDL cholesterol, and triglycerides, and promote beneficial GM changes.
These may contribute to the metabolic benefits of the MedD.
Future research should focus on individualized approaches, longer intervention periods, and mechanistic insights using multi-omics data to better understand the diet-microbiota-host interaction.
With further progress in standardization and safety validation, they may become reliable and personalized tools for promoting gut and overall health.
Rana A et al. · Journal of the science of food and agriculture (2026)
Future research must address these challenges through large scale, well controlled trials that clarify strain dependent mechanisms and establish standardized recommendations.
Advances in microbiome science also highlight the potential of next generation probiotics such as Faecalibacterium prausnitzii and Akkermansia muciniphila, which may extend benefits beyond conventional strains.
In conclusion, probiotics represent a promising adjunct to conventional therapies for gastrointestinal disorders.
By addressing these factors, the review seeks to provide realistic perspectives on its therapeutic potential and to outline directions for future research.
Mierlan OL, Busila C, Amaritei O, Elena D, Raileanu CR, Maftei NM, Matei MN, Gurau G. · International journal of molecular sciences (2025)
While associations have been consistently observed in both rodent and human studies, causality has thus far been demonstrated only in animal models.
This issue is of critical importance, as metabolic disease remains highly prevalent, carries systemic consequences, and imposes a substantial burden on healthcare systems, underscoring the urgent need for alternative therapeutic strategies.
The aim of this narrative review is to synthesize current knowledge on A. muciniphila and to highlight the key limitations consistently reported in the literature.
Furthermore, we address the critical challenges regarding strain-specific efficacy and ecological impacts, providing a strategic roadmap for the clinical translation of A. muciniphila into the next frontier of precision microbiome medicine.
Kim TH, Kim SM, Kim MH. · Journal of microbiology and biotechnology (2026)
This review provides a comprehensive synthesis of recent breakthroughs in identifying A. muciniphila -derived bioactive effectors, including structural components, secreted enzymes, and signaling peptides.
We examine how these molecular postbiotics orchestrate host health by reinforcing intestinal barrier integrity, modulating systemic immune responses, and reprogramming the tumor microenvironment.
By integrating these multifaceted modes of action into a unified framework, we evaluate the therapeutic potential of both live bacteria and cell-free derivatives.
Current evidence supports that appendicitis may represent a disease spectrum carrying multiple rather than a single microbial signature that dictates different pathophysiologic processes.
Karikis I et al. · Surgical infections (2026)
Current evidence supports that appendicitis may represent a disease spectrum carrying multiple rather than a single microbial signature that dictates different pathophysiologic processes.
This review provides a theoretical foundation and future perspectives for in-depth research investigation and clinical application of A. muciniphila disease-related proteins.
Han Y, Lu J, Bu X, Hu L, Niu C, Qiao J, Wu H, Caiyin Q. · Microorganisms (2026)
As a representative next-generation probiotic, Akkermansia muciniphila ( A. muciniphila ) produces a variety of functional proteins that play critical roles in the prevention and treatment of multiple diseases, including metabolic disorders, inflammatory diseases, neurological disorders, and cancer.
This review summarizes the disease-associated proteins of A. muciniphila reported to date, including the outer membrane proteins Amuc_1100 and Amuc_1098, as well as the secreted proteins P9 (Amuc_1631), P5, Amuc_1409, Amuc_1434, and Amuc_2109.
This review provides a theoretical foundation and future perspectives for in-depth research investigation and clinical application of A. muciniphila disease-related proteins.
Clinical use will need human studies at the strain level, confirmation in humanized models, and early trials using biomarkers to test safety and causal effects.
Li J, Long Q, Zhu B. · Biomolecules (2026)
This review summarizes mechanistic, preclinical, and translational evidence connecting A. muciniphila to AD, including products such as short-chain fatty acids (SCFAs), and structural or secreted proteins including Amuc_1100 and extracellular vesicles (AmEVs).
We also discuss differences between bacterial strains, differences in research methods, and findings that change under different conditions, which make the results harder to interpret.
Animal studies suggest neuroprotective effects, but clinical evidence is still limited.
This strategy offers new avenues for linking fundamental gut microbiome research with translational metabolic medicine applications.
Long Z, Li J, Zhu F, Liu X, Zhou J, Li J, Xu W. · International journal of biological macromolecules (2026)
In addition, we explore the modular structure of P9 proteins predicted by AlphaFold, revealing potential domains amenable to functional optimization through protein engineering.
By combining mechanistic insights with bioengineering approaches, this review positions engineered P9 as a multifunctional candidate for developing oral, targeted, and sustained-release therapies against obesity and type 2 diabetes mellitus (T2DM).
This strategy offers new avenues for linking fundamental gut microbiome research with translational metabolic medicine applications.
Reconciling this microbial Janus face may pave the way for novel microbiome-based precision therapeutics against neurodegeneration.
Chen N, Pang D, Shang H. · Microbiological research (2026)
This review synthesizes evidence on A. muciniphila's structural components, its divergent associations with PD phenotypes, and the dietary and host factors shaping its abundance from gestation to senescence.
We propose a lifespan-targeted intervention model that strategically modulates A. muciniphila, which could concurrently mitigate PD progression and promote healthy aging.
We suggest suppressing its neurotoxic pathways in susceptible individuals while enhancing its beneficial functions in the aging process.
This review synthesizes current advances linking the gut microbiome to HCC immunobiology and highlights emerging therapeutic strategies aimed at optimizing immunotherapy through precise microbial modulation.
Wu M et al. · Cancer biology & medicine (2026)
Tryptophan catabolites, acting via the aryl hydrocarbon receptor (AhR), further fine tune immune and barrier functions.
In addition, emerging data implicate intratumoral microbiota as active modulators of immune suppression and metastatic behavior.
These mechanistic insights have accelerated the development of microbiome-targeted interventions, such as probiotics, prebiotics, engineered bacterial strains, and fecal microbiota transplantation, to enhance ICB responsiveness.
Understanding the ecological niches and molecular interactions of MD bacteria offers promising approaches for microbiota-targeted therapies aimed at restoring gut and systemic homeostasis.
Tiffany E et al. · Gut microbes (2026)
These bacteria influence intestinal homeostasis by modulating epithelial cell differentiation, immune responses, and gut microbiota composition through mucin degradation and the production of bioactive metabolites.
Their abundance and functional activities fluctuate dynamically in response to dietary components, host immunity, and environmental factors, resulting in context-dependent effects on gastrointestinal and systemic health.
This review summarizes current insights into the ecology and metabolic capabilities of MD bacteria, highlighting their dual roles in metabolic disorders, inflammatory diseases, infection susceptibility, and neuroimmune conditions.
Conclusions The AKK formula increased the relative abundance of A. muciniphila , was associated with selective modulation of gut microbiota composition, and showed a trend toward reduced gastrointestinal discomfort, supporting its potential relevance in future gut health research.
Wu CK, Cheng IS, Chung YC, Liu MF, Lin YK, Lin YH, Morris K, Chang D, Chiang CF, Yang MT. · International journal of medical sciences (2026)
The AKK formula group showed an increased qPCR-derived relative abundance of A. muciniphila compared with total bacteria.
Gut microbiome analysis further demonstrated selective changes in gut microbiota composition in the AKK formula group, including an increased relative abundance of Bifidobacterium and decreased relative abundances of Proteobacteria , Erysipelotrichia , and Escherichia-Shigella .
A trend toward lower gastrointestinal discomfort scores was observed in the AKK formula group during the intervention period.
A clearer understanding of strain identity, active therapeutic entities, delivery strategies, and host context will be essential for advancing this dual-target microbial strategy toward clinically meaningful applications.
Liu S, Wang M, Sun X, Jia Z, Huang K. · Metabolites (2026)
We further highlight the ecological rationale for their functional complementarity and discuss priorities for future combination studies and precision implementation.
Overall, the available literature supports functional complementarity and possible additive metabolic benefits, but synergistic effects in humans remain unconfirmed.
A clearer understanding of strain identity, active therapeutic entities, delivery strategies, and host context will be essential for advancing this dual-target microbial strategy toward clinically meaningful applications.